4.4 Article

Protective effect of teprenone on gastric mucosal injury induced by dual antiplatelet therapy in rats

Journal

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
Volume 13, Issue 4, Pages 2702-2709

Publisher

E-CENTURY PUBLISHING CORP

Keywords

Teprenone; aspirin; clopidogrel; rats; gastric mucosal injury

Funding

  1. Science and Technology Program of Quanzhou [2018Z045]

Ask authors/readers for more resources

Teprenone protects against gastric mucosal injury induced by dual antiplatelet therapy through inhibiting gastric mucosal inflammation, inhibiting oxidative stress, and improving gastric mucosa indices.
Objective: To investigate the protective effect of teprenone on gastric mucosal injury induced by dual antiplatelet therapy in rats. Methods: Healthy, specifically pathogen free SD, rats were selected and divided into 4 groups: Normal group (normal rats, without any treatment), Model group (rats received dual antiplatelet therapy: aspirin and clopidogrel), Teprenone group (rats received dual antiplatelet therapy and teprenone) and Pantoprazole group (rats received dual antiplatelet therapy and pantoprazole). The gastric mucosal blood flow, ulcer index, gastric gel mucus thickness, the levels of gastrin (Gas), prostaglandin (PG), prostaglandin E-2 (PGE(2)), endothelin-1 (ET-1) tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6 and IL-10 in serum, the levels of malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD) and myeloperoxidase (MPO) in the gastric mucosa, as well as the expression of vascular endothelial growth factor (VEGF) in the rat's stomach were measured. Results: Compared with the Normal group, the other groups showed more severe gastric injury, elevated levels of inflammatory factors (TNF-alpha, IL-1 beta, IL-6 and IL-10), elevated levels of MDA and MPO, as well as reduced levels of GSH, SOD and VEGF (all P<0.05). Compared with the Model group, the gastric mucosal lesions in the Teprenone group and the Pantoprazole group were improved significantly (both P<0.05). Compared with the Pantoprazole group, the Teprenone group had reduced levels of ET-1 and elevated levels of PG and PGE(2) (all P<0.05). Conclusion: Teprenone protects against gastric mucosal injury induced by dual antiplatelet therapy through inhibiting gastric mucosal inflammation inhibiting oxidative stress and improving gastric mucosa indices.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available